

Eucrisa (crisaborole)

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Eucrisa (crisaborole)	1
Summary	1
Definitions	2
Clinical Indications	4
Medical Necessity Criteria for Initial Clinical Review	4
Initial Indication-Specific Criteria	4
Mild to Moderate Atopic Dermatitis	4
Medical Necessity Criteria for Subsequent Clinical Review	4
Subsequent Indication-Specific Criteria	4
Mild to Moderate Atopic Dermatitis	4
Experimental or Investigational or Unproven / Not Medically Necessary	5
References	5
Clinical Guideline Revision / History Information	7

Summary

Atopic dermatitis (AD), commonly known as eczema, is a chronic, inflammatory skin disorder that affects approximately 10% of adults and 20% of children worldwide. It is characterized by intense itching, redness, and eczematous lesions, which can be accompanied by skin dryness, scaling, and thickening. The clinical course of AD is characterized by chronic, relapsing episodes over months to years. In mild cases, one may experience intermittent flares that may or may not clear without the use of pharmacological intervention. In more moderate and severe cases, flares rarely clear without pharmacological intervention/therapy. The severity of AD can be classified as mild, moderate, or severe, depending on the extent and intensity of skin inflammation, as well as the impact on the patient's quality of life. Moderate-to-severe AD is defined by the presence of extensive or widespread lesions, intense pruritus, and a significant impairment of daily activities, sleep, and mood. Its pathology involves a combination of skin barrier dysfunction, immune dysregulation, and environmental and genetic factors. AD is often associated with other atopic disorders such as asthma and allergic rhinitis.

AD presents differently across age groups, with acute, subacute, and chronic stages. In infants and toddlers, it typically affects the face, scalp, and extensor surfaces of the extremities, while in older children and adults, it tends to localize to the flexural areas. It is a relapsing disease, with flares commonly triggered by irritants, allergens, infections, and stress.

Standard treatment of AD involves a combination of skin care practices, trigger avoidance, and pharmacologic interventions. The cornerstone of AD management includes regular use of moisturizers to enhance the skin barrier and reduce dryness and pruritus. Mild to moderate AD is typically managed with topical medications, which may include topical corticosteroids and calcineurin inhibitors such as tacrolimus. More severe cases may necessitate systemic treatments such as systemic corticosteroids, immunosuppressants, or newer biologic therapies.

Eucrisa (crisaborole) is a non-steroidal, anti-inflammatory phosphodiesterase-4 inhibitor for topical use. It has been approved for the treatment of mild to moderate atopic dermatitis in those 3 months of age and older. Eucrisa (crisaborole) works by reducing inflammation and increasing hydration in the skin. Its primary advantage is its safety profile, which is notably devoid of the adverse effects commonly associated with prolonged use of topical corticosteroids, such as skin atrophy. The most common side effect is skin irritation at the application site, including symptoms such as pain, burning, or stinging.

Definitions

"Atopic Dermatitis" also known as eczema is a chronic skin condition that makes a person's skin red, itchy and scaly. Atopic dermatitis (AD) often begins during childhood and persists into adulthood. Some people experience occasional flares followed by periods of improvement or a "waxing and waning" course of the disease.

"Biologics" "Biologicals" or "Biological therapeutics" as defined by the World Health Organization (WHO) are a class of medicines which are grown and then purified from large-scale cell cultures such as

bacteria, yeast, animal or plant cells. Biologics can include but are not limited to vaccines, growth factors, immune modulators, and monoclonal antibodies. Unlike other medicines, biologics are generally proteins purified from living culture systems and/or blood, and are often referred to as "large molecules."

"Body surface area (BSA)" is a measure of the total area involved by plaques in relation to the total body surface area. There are a number of different methods, however most clinical trials on plaque psoriasis use the "handprint method", where the patient's actual palm/hand size is estimated as 1% of BSA. The head and neck, upper extremities, trunk, and lower extremities (including buttocks) typically correspond to approximately 10%, 20%, 30% and 40% of the BSA, respectively.

"Calcineurin Inhibitors" are immunomodulating drugs used topically in the management of atopic dermatitis, such as tacrolimus and pimecrolimus. They suppress the activity of the immune system and decrease inflammation, but are generally used when topical corticosteroids are ineffective or contraindicated.

"Documentation" refers to written information, including but not limited to:

- Up-to-date chart notes, relevant test results, and/or relevant imaging reports to support diagnoses; or
- Prescription claims records, and/or prescription receipts to support prior trials of formulary alternatives.

"Erythema" refers to the redness of the skin caused by increased blood flow in the superficial capillaries. In atopic dermatitis, erythema is a sign of inflammation.

"Excoriation" refers to chafing, picking, scratching or scraping of the skin, resulting in raw, irritated and sometimes painful lesions. "Exudation" is the oozing of fluid, usually serous fluid, which can occur in acute phases of atopic dermatitis when vesicles or blisters rupture.

"Induration" refers to the thickening of tissues, usually due to inflammation or edema. This commonly occurs on the hands and face, but can occur on the chest, back, abdomen, breasts and buttocks.

"Lichenification" refers to skin thickening with accentuation of skin markings, often a consequence of chronic scratching or rubbing in conditions like atopic dermatitis.

"Papulation" refers to the process of papule (a small, solid, raised bump) formation on the skin.

"Pruritus" refers to itchiness, a common and distressing symptom of atopic dermatitis that can significantly affect quality of life.

"Topical Corticosteroids" are medications applied directly to the skin to reduce inflammation and irritation. They are a mainstay of treatment for atopic dermatitis but can have side effects with prolonged use, such as skin thinning.

"Xerosis" refers to abnormally dry skin, a characteristic feature of atopic dermatitis. Regular use of moisturizers is recommended to combat xerosis in AD management.

"[s]" indicates state mandates may apply.

Clinical Indications

Medical Necessity Criteria for Initial Clinical Review

Initial Indication-Specific Criteria

Mild to Moderate Atopic Dermatitis

The Plan considers Eucria (crisaborole) medically necessary when ALL of the following criteria are met:

1. The member has a diagnosis of mild to moderate atopic dermatitis; *AND*
2. The member meets ONE (1) of the following:
 - a. The member is unable to use, or has tried and failed BOTH of the following^[s]:
 - i. A topical corticosteroid; *and*
 - ii. A topical calcineurin inhibitor (such as tacrolimus); *or*
 - b. The member requires treatment in an affected area that is considered sensitive (such as the face/neck, axillae, skin fold, or groin) *AND* the member is unable to use, or has tried and failed a topical calcineurin inhibitor (such as tacrolimus).

If the above prior authorization criteria are met, Eucria (crisaborole) will be approved for up to 6 months.^[s]

Continued Care

Medical Necessity Criteria for Subsequent Clinical Review

Subsequent Indication-Specific Criteria

Mild to Moderate Atopic Dermatitis

The Plan considers Eucria (crisaborole) medically necessary when the following criteria are met:

1. The member is responding positively to Eucria (crisaborole) treatment based upon the prescriber's assessment as demonstrated by ONE (1) of the following:
 - a. Reduction in body surface area involvement of atopic dermatitis lesions; *or*
 - b. Decrease in pruritus severity; *or*
 - c. Improvement in signs and symptoms of atopic dermatitis, such as erythema, exudation, excoriation, induration/papulation, and lichenification.

If the above reauthorization criteria are met, the requested product will be authorized for up to 12 months.^[s]

Experimental or Investigational or Unproven / Not Medically Necessary^[s]

Eucrisa (crisaborole) for any other indication is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, unproven, or not medically necessary.

References

1. AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel; Chu DK, Schneider L, Asiniwasis RN, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. *Ann Allergy Asthma Immunol.* 2024 Mar;132(3):274-312. doi: 10.1016/j.anai.2023.11.009. Epub 2023 Dec 18. PMID: 38108679.
2. Ahmed, A., et al. Magnitude of Benefit for Topical Crisaborole in the Treatment of Atopic Dermatitis in Children and Adults Does Not Look Promising: A Critical Appraisal. *British Journal of Dermatology*, vol. 178, 2018, pp. 659.
3. Bieber, T. Atopic Dermatitis: An Expanding Therapeutic Pipeline for a Complex Disease. *Nature Reviews Drug Discovery*, vol. 20, 2021, pp. 1-20.
4. Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. *Ann Allergy Asthma Immunol.* 2018 Jan;120(1):10-22.e2. doi: 10.1016/j.anai.2017.10.039. PMID: 29273118.
5. Boguniewicz M, Levy ML, Eichenfield LF, et al. Managing Childhood and Adolescent Atopic Dermatitis in Primary Care: A US Expert Group Consensus. *J Pediatr Clin Pract.* 2024 Jul 10;14:200121. doi: 10.1016/j.jpdc.2024.200121.
6. Butala S, Paller AS. Optimizing topical management of atopic dermatitis. *Ann Allergy Asthma Immunol.* 2022 May;128(5):488-504. doi: 10.1016/j.anai.2022.03.004. Epub 2022 Mar 12.
7. Draelos ZD, Feldman SR, Berman B, et al.,. Tolerability of Topical Treatments for Atopic Dermatitis. *Dermatol Ther (Heidelb).* 2019 Mar;9(1):71-102. doi: 10.1007/s13555-019-0280-7. Epub 2019 Jan 24.
8. Drucker, A. M., et al. Systemic Immunomodulatory Treatments for Patients with Atopic Dermatitis: A Systematic Review and Network Meta-Analysis. *JAMA Dermatology*, Apr. 2020, <https://doi.org/10.1001/jamadermatol.2020.0435>.
9. Eichenfield, L. F., et al. Guidelines of Care for the Management of Atopic Dermatitis: Section 2. Management and Treatment of Atopic Dermatitis with Topical Therapies. *Journal of the American Academy of Dermatology*, vol. 71, 2014, pp. 116.
10. Eichenfield, L. F., et al. Long-Term Safety of Crisaborole Ointment 2% in Children and Adults with Mild to Moderate Atopic Dermatitis. *Journal of the American Academy of Dermatology*, vol. 77, 2017, pp. 641.
11. Eichenfield LF, Gower RG, Xu J, et al.,. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study. *Am J Clin Dermatol.* 2023 Jul;24(4):623-635. doi: 10.1007/s40257-023-00780-w. Epub 2023 May 15.
12. Eichenfield LF, Yosipovitch G, Stein Gold LF, et al.,. Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis. *Pediatr Dermatol.* 2020 Nov;37(6):1030-1037. doi: 10.1111/pde.14328. Epub 2020 Sep 27.

13. Eucrisa Ointment 2% (crisaborole) [prescribing information]. New York, NY: Pfizer Labs; April 2023.
14. Fishbein, A. B. Management of Atopic Dermatitis in Children Younger Than Two Years of Age by Community Pediatricians: A Survey and Chart Review. *The Journal of Pediatrics*, vol. 221, 2020, pp. 138-144.
15. Frazier, W., and Bhardwaj, N. Atopic Dermatitis: Diagnosis and Treatment. *American Family Physician*, vol. 101, no. 10, 2020, pp. 590-598.
16. Hanna, S., et al. What Is the Risk of Harm Associated With Topical Calcineurin Inhibitors? *Journal of Cutaneous Medicine and Surgery*, first published September 3, 2019, <https://doi.org/10.1177/1203475419857688>.
17. Hashim PW, Chima M, Kim HJ, et al,. Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial. *J Am Acad Dermatol*. 2020 Feb;82(2):360-365. doi: 10.1016/j.jaad.2019.06.1288. Epub 2019 Jul 3.
18. Hong, C., et al. Evidence Review of Topical Calcineurin Inhibitors for the Treatment of Adult Atopic Dermatitis. *Journal of Cutaneous Medicine and Surgery*, <https://doi.org/10.1177/1203475419857669>.
19. Johnson, B. B., et al. Treatment-Resistant Atopic Dermatitis: Challenges and Solutions. *Clinical, Cosmetic and Investigational Dermatology*, vol. 12, 2019, pp. 181.
20. Kolb, L., and Ferrer-Bruker, S. J. Atopic Dermatitis. StatPearls, updated 2021, StatPearls Publishing, 2022, <https://www.ncbi.nlm.nih.gov/books/NBK448071/>.
21. Lansang P, Lara-Corrales I, Bergman JN, et al. Approach to the Assessment and Management of Pediatric Patients With Atopic Dermatitis: A Consensus Document. Section IV: Consensus Statements on the Assessment and Management of Pediatric Atopic Dermatitis. *J Cutan Med Surg*. 2019 Nov/Dec;23(5_suppl):32S-39S. doi: 10.1177/1203475419882654. Erratum in: *J Cutan Med Surg*. 2020 Jan/Feb;24(1):107. doi: 10.1177/1203475419893992.
22. Lax SJ, Van Vogt E, Candy B, et al. Topical Anti-Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta-Analysis. *Clin Exp Allergy*. 2024 Dec;54(12):960-972. doi: 10.1111/cea.14556. Epub 2024 Sep 2.
23. Luger, T., et al. Unmet Medical Needs in the Treatment of Atopic Dermatitis in Infants: An Expert Consensus on Safety and Efficacy of Pimecrolimus. *Pediatric Allergy and Immunology*, vol. 32, no. 3, 2021, pp. 414-424.
24. National Institute for Health and Care Excellence (NICE). Atopic eczema in under 12s: diagnosis and management [CG57]. 12 Dec 2007, updated 22 Sep 2025. Available at: <https://www.nice.org.uk/guidance/cg57/chapter/Recommendations-for-research#early-intervention>. Accessed 16 Mar 2026.
25. Oscherwitz M, Gadre A, Martino A, Zirwas M, Feldman S. Topical Treatment of Atopic Dermatitis: An Adherence-Based Appraisal of the AAD Guidelines. *J Drugs Dermatol*. 2024 Oct 1;23(10):897-898.
26. Paller AS, Tom WL, Lebwohl MG, et al,. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. *J Am Acad Dermatol*. 2016 Sep;75(3):494-503.e6. doi: 10.1016/j.jaad.2016.05.046. Epub 2016 Jul 11.
27. Pao-Ling Lin C, Gordon S, Her MJ, Rosmarin D. A retrospective study: Application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor. *J Am Acad Dermatol*. 2019 May;80(5):1451-1453. doi: 10.1016/j.jaad.2018.10.054. Epub 2018 Nov 2.
28. Schlessinger, J., et al. Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to <24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1). *American Journal of Clinical Dermatology*, vol. 21, 2020, pp. 275.
29. Seger, E. W., et al. Relative Efficacy of Systemic Treatments for Atopic Dermatitis. *Journal of the American Academy of Dermatology*, vol. 80, 2019, pp. 411.
30. Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. *J Am Acad Dermatol*. 2023 Jul;89(1):e1-e20. doi: 10.1016/j.jaad.2022.12.029. Epub 2023 Jan 12.

31. Stein Gold LF, Tom WL, Shi V, et al. Impact of Crisaborole in Treatment-Experienced Patients With Mild-to-Moderate Atopic Dermatitis. *Dermatitis*. 2024 Jan-Feb;35(1):84-91. doi: 10.1089/derm.2023.0112. Epub 2024 Jan 11.
32. Wolf J, Chen A, Wieser J, et al,. Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis. *J Eur Acad Dermatol Venereol*. 2024 Jul;38(7):1364-1372. doi: 10.1111/jdv.19807. Epub 2024 Feb 15.
33. Wollenberg A, Christen-Zäch S, Taieb A, et al,. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. *J Eur Acad Dermatol Venereol*. 2020 Dec;34(12):2717-2744. doi: 10.1111/jdv.16892. Epub 2020 Nov 17.
34. Wollenberg A, Kinberger M, Arents B, et al,. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. *J Eur Acad Dermatol Venereol*. 2022 Nov;36(11):1904-1926. doi: 10.1111/jdv.18429. Epub 2022 Sep 3.
35. Zane LT, Kircik L, Call R, et al,. Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study. *Pediatr Dermatol*. 2016 Jul;33(4):380-7. doi: 10.1111/pde.12872. Epub 2016 May 18.

Clinical Guideline Revision / History Information

Original Date: 08/06/2020

Reviewed/Revised: 06/24/2021, 12/01/2021, 06/23/2022, 06/29/2023, 06/27/2024,
10/01/2025, 09/01/2026